ABACUS

Title: A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder
Disease site: Bladder cancer
Status: In follow up

Trial Design: Open-label, international, multicentre window of opportunity phase II trial that aims to evaluate the effects of short-term preoperative therapy with atezolizumab in patients with histologically confirmed (T2-T4a) transitional cell carcinoma of the bladder. Eligible patients will receive 2 x 3 weekly cycles of atezolizumab pre-cystectomy and will be followed up for 2 years post cystectomy to collect survival and disease status data. The efficacy of atezolizumab will be assessed on CT/MRI scan images and tumour tissue samples collected at baseline and after treatment with atezolizumab. ABACUS includes an extensive translational program.

ABACUS met its primary endpoint and study result were reported as an oral abstract at ASCO 2018. Patients continue to be in follow up.

Trial details

Chief Investigator: Prof T. Powles
Trial contact: bci-abacus@qmul.ac.uk
Clinical Trials.gov: NCT02662309
EudraCT: 2015-001112-35
Sponsor: Queen Mary University of London
Participating countries: UK, Spain, The Netherlands, France
Source of funding: F. Hoffmann-La Roche Ltd (funding and study drug)

Publications and presentations

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). Thomas Powles, Alejo Rodriguez-Vida, Ignacio Duran et al. Journal of Clinical Oncology (2018) 36:15_suppl, 4506 - 4506

Patient friendly information

Cancer Research UK website  A trial looking at MPDL3280A before surgery for bladder cancer (ABACUS)

Clinical Trial Portfolio

Click here to to see a list of our clinical trials that are currently in set up or those that are open to recruitment.